Gritstone Oncology, Inc.

Gritstone Oncology, Inc. insiders are currently net buyers of GRTS stock, showing bullish sentiment over the past 90 days. Executives have purchased $15.0M while selling $1.4M, resulting in a positive net flow of $13.7M. This buying activity represents 92% of total transaction volume.

Gritstone Oncology, Inc. has 23 active insiders who have filed SEC Form 4 transactions in the past 90 days. Thomas Woiwode (Executive) leads with 8 transactions totaling $5.0M. Lifesciences Iii, L.p. Clarus (Executive) follows with 2 transactions worth $5.0M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. Gritstone Oncology, Inc.'s current score of 92/100 indicates bullish insider sentiment. Scores above 60 suggest insiders are accumulating shares faster than selling, reflecting $15.0M in purchases versus $1.4M in sales.

The most recent insider transaction occurred on Jun 24, 2024, when R. Allen Andrew (Executive) disposed of 325,000 shares at $0.00 per share for $0. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, GRTS insider trading sentiment is currently bullish with an Alignment Score of 92/100. The net insider flow of $13.7M reflects accumulation, with 92% of volume being purchases.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like Gritstone Oncology, Inc.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At GRTS, we track all Form 4 filings—currently showing 110 transactions from 23 insiders over 90 days.

A 10b5-1 plan allows Gritstone Oncology, Inc. executives to pre-schedule stock sales when they don't possess material non-public information. At GRTS, approximately 0% of recent transactions are 10b5-1 trades. Most trading activity at GRTS appears discretionary, making insider signals more meaningful.

You can monitor Gritstone Oncology, Inc. (GRTS) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 23 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. Gritstone Oncology, Inc.'s current score of 92/100 indicates strong bullish sentiment with executives accumulating shares. This is calculated from $15.0M in purchases versus $1.4M in sales over 90 days, resulting in a net flow of $13.7M.

SEC Form 4 filings are mandatory reports that Gritstone Oncology, Inc. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At GRTS, the most common type is "A" with 42 occurrences. The most recent Form 4 was filed on Jun 24, 2024 by R. Allen Andrew.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At Gritstone Oncology, Inc., approximately 0% of recent transactions are executed under 10b5-1 plans, while 100% appear to be discretionary trades. The low percentage means most insider activity at GRTS represents discretionary decisions with more informational value.